Immunovant, Inc.

NASDAQ:IMVT

28.9 (USD) • At close September 18, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2024202320222021202020192018
Operating Activities:
Net Income -259.336-210.96-156.73-107.431-66.388-28.599-136.74
Depreciation & Amortization 0.2310.1930.1260.0650.0210.010
Deferred Income Tax 000-0.282000
Stock Based Compensation 41.11632.29634.24418.8226.9631.3081.812
Change In Working Capital 2.632-10.85315.1424.5664.806-0.4741.443
Accounts Receivables -4.55811.764-11.633-0.596-0.08300
Inventory 0000.5960.08300
Accounts Payables 5.784-17.12416.2541.2510.96700
Other Working Capital 1.4065.3610.5213.3153.839-0.4741.443
Other Non Cash Items 41.4821.1311.1060.9331.241-0.7925.187
Operating Cash Flow -214.227-188.193-106.112-83.327-53.357-28.547-128.297
Investing Activities:
Investments In Property Plant And Equipment -0.36-0.197-0.254-0.21-0.031-0.0520
Acquisitions Net 0000000
Purchases Of Investments 0000000
Sales Maturities Of Investments 0000000
Other Investing Activites 0000000
Investing Cash Flow -0.36-0.197-0.254-0.21-0.031-0.0520
Financing Activities:
Debt Repayment 000-3.19-500
Common Stock Issued 472.42770.50.129319.783-1.9500
Common Stock Repurchased 0000000
Dividends Paid 0000000
Other Financing Activities -6.0120.38520066.519153.92435.584128.297
Financing Cash Flow 472.42770.885200.129383.112146.97435.584128.297
Other Information:
Effect Of Forex Changes On Cash 0.9930.22-0.0920000
Net Change In Cash 258.833-117.28593.671299.57593.5866.9850
Cash At End Of Period 635.365376.532493.817400.146100.5716.9850